$79.14 Million in Sales Expected for Pacira Pharmaceuticals Inc (PCRX) This Quarter

Analysts expect Pacira Pharmaceuticals Inc (NASDAQ:PCRX) to announce sales of $79.14 million for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Pacira Pharmaceuticals’ earnings. The lowest sales estimate is $79.00 million and the highest is $79.42 million. Pacira Pharmaceuticals reported sales of $72.90 million during the same quarter last year, which indicates a positive year-over-year growth rate of 8.6%. The firm is scheduled to issue its next earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Pacira Pharmaceuticals will report full year sales of $79.14 million for the current fiscal year, with estimates ranging from $282.76 million to $287.00 million. For the next financial year, analysts forecast that the business will post sales of $329.26 million per share, with estimates ranging from $311.89 million to $357.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. During the same period last year, the firm posted $0.20 earnings per share. The business’s revenue was down 1.6% on a year-over-year basis.

A number of analysts have recently issued reports on PCRX shares. Bank of America cut their price objective on Pacira Pharmaceuticals from $46.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, October 4th. Zacks Investment Research cut Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 9th. Royal Bank of Canada reissued a “buy” rating and set a $54.00 price target on shares of Pacira Pharmaceuticals in a report on Friday, October 13th. Needham & Company LLC dropped their price target on Pacira Pharmaceuticals from $55.00 to $52.00 and set a “buy” rating for the company in a report on Thursday, October 19th. Finally, Wedbush reissued an “outperform” rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, October 25th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $48.82.

In other Pacira Pharmaceuticals news, SVP James B. Jones sold 850 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $41.11, for a total transaction of $34,943.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Mark A. Kronenfeld acquired 1,000 shares of the stock in a transaction on Friday, November 10th. The shares were bought at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the purchase, the director now owns 6,795 shares in the company, valued at $282,672. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 98,960 shares of company stock worth $3,868,341. Corporate insiders own 6.60% of the company’s stock.

A number of institutional investors have recently bought and sold shares of PCRX. Cubist Systematic Strategies LLC increased its stake in Pacira Pharmaceuticals by 121.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after acquiring an additional 1,752 shares during the period. QS Investors LLC bought a new position in Pacira Pharmaceuticals during the 2nd quarter worth $157,000. Ameritas Investment Partners Inc. increased its stake in Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after acquiring an additional 302 shares during the period. Spectrum Management Group Inc. bought a new position in Pacira Pharmaceuticals during the 3rd quarter worth $166,000. Finally, Bouchey Financial Group Ltd bought a new position in Pacira Pharmaceuticals during the 4th quarter worth $205,000.

Shares of Pacira Pharmaceuticals (NASDAQ PCRX) opened at $36.40 on Thursday. Pacira Pharmaceuticals has a 52-week low of $29.81 and a 52-week high of $58.95. The stock has a market capitalization of $1,480.00, a P/E ratio of -27.79 and a beta of 2.20. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24.

TRADEMARK VIOLATION NOTICE: “$79.14 Million in Sales Expected for Pacira Pharmaceuticals Inc (PCRX) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/01/79-14-million-in-sales-expected-for-pacira-pharmaceuticals-inc-pcrx-this-quarter.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply